The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells

Br J Haematol. 1995 Jul;90(3):707-10. doi: 10.1111/j.1365-2141.1995.tb05605.x.

Abstract

In order to understand the mechanisms supporting steroid escape in patients with multiple myeloma (MM), three IL-6 autocrine human myeloma cell lines, LP1, OPM2 and L363, have been treated with dexamethasone in the presence or absence of cytokines belonging to the gp 130 family: IL-6, LIF, OSM and IL-11. With pharmacological doses of dexamethasone, a dramatic growth arrest was observed in all the cell lines. IL-6 completely reversed this inhibition. Of note, this IL-6 induced reversion was still seen with very low amounts of IL-6 (12 pg/ml). Finally, whereas LIF and OSM had clear growth-promoting effects on OPM2 only, both cytokines (but not IL-11) reversed the dexamethasone-induced growth arrest in all the cell lines. Therefore the high levels of IL-6 (ng/ml) observed in the MM intermediate milieu and the putative presence of LIF and OSM can easily counteract the effects of dexamethasone in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Cell Division / drug effects
  • Dexamethasone / pharmacology*
  • Growth Inhibitors / pharmacology*
  • Humans
  • Interleukin-11 / pharmacology*
  • Interleukin-6 / pharmacology*
  • Leukemia Inhibitory Factor
  • Lymphokines / pharmacology*
  • Multiple Myeloma / pathology*
  • Oncostatin M
  • Peptides / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Growth Inhibitors
  • Interleukin-11
  • Interleukin-6
  • LIF protein, human
  • Leukemia Inhibitory Factor
  • Lymphokines
  • OSM protein, human
  • Peptides
  • Oncostatin M
  • Dexamethasone